1 | as per customer specification | | | | | | | 7 | 0.92% |
2 | or as per customer | | | | | | | 7 | 0.92% |
3 | tablets or as per | | | | | | | 5 | 0.66% |
4 | film coated tablets product | | | | | | | 3 | 0.39% |
5 | tablets product information therapeutic | | | | | | | 3 | 0.39% |
6 | imperia lifesciences pvt ltd | | | | | | | 3 | 0.39% |
7 | coated tablets product information | | | | | | | 3 | 0.39% |
8 | for the treatment of | | | | | | | 3 | 0.39% |
9 | product information therapeutic indications | | | | | | | 3 | 0.39% |
10 | 10 tablets or as | | | | | | | 3 | 0.39% |
11 | mg film coated tablets | | | | | | | 3 | 0.39% |
12 | complex akshar chowk op | | | | | | | 2 | 0.26% |
13 | lifesciences pvt ltd ils | | | | | | | 2 | 0.26% |
14 | earth complex akshar chowk | | | | | | | 2 | 0.26% |
15 | 100 mg167 ml300 mg50 | | | | | | | 2 | 0.26% |
16 | prevention of recurrent dvt | | | | | | | 2 | 0.26% |
17 | of recurrent dvt and | | | | | | | 2 | 0.26% |
18 | mg167 ml300 mg50 ml | | | | | | | 2 | 0.26% |
19 | prevention of stroke and | | | | | | | 2 | 0.26% |
20 | and systemic embolism in | | | | | | | 2 | 0.26% |
21 | stroke and systemic embolism | | | | | | | 2 | 0.26% |
22 | of stroke and systemic | | | | | | | 2 | 0.26% |
23 | signetthe business hub near | | | | | | | 2 | 0.26% |
24 | of deep vein thrombosis | | | | | | | 2 | 0.26% |
25 | therapeutic indications for the | | | | | | | 2 | 0.26% |
26 | indications for the treatment | | | | | | | 2 | 0.26% |
27 | 2 mg 4 mg | | | | | | | 2 | 0.26% |
28 | treatment of deep vein | | | | | | | 2 | 0.26% |
29 | x 10 tablets or | | | | | | | 2 | 0.26% |
30 | mg tablets product information | | | | | | | 2 | 0.26% |
31 | 6021 signetthe business hub | | | | | | | 2 | 0.26% |
32 | toggle navigation home about | | | | | | | 1 | 0.13% |
33 | should have included an | | | | | | | 1 | 0.13% |
34 | have included an anthracycline | | | | | | | 1 | 0.13% |
35 | unless clinically contraindicated pharmacotherapeutic | | | | | | | 1 | 0.13% |
36 | clinically contraindicated pharmacotherapeutic group | | | | | | | 1 | 0.13% |
37 | contraindicated pharmacotherapeutic group oral | | | | | | | 1 | 0.13% |
38 | salts ors 206g pack | | | | | | | 1 | 0.13% |
39 | ors 206g pack style | | | | | | | 1 | 0.13% |
40 | rehydration salts ors 206g | | | | | | | 1 | 0.13% |